Caribou Biosciences explores strategic alternatives, drawing interest as a reverse-merger candidate

Caribou Biosciences, the cell‑therapy company co‑founded by CRISPR pioneer Jennifer Doudna, announced it is evaluating strategic alternatives as it faces a difficult financing environment.

The company said securing capital to advance its two primary off‑the‑shelf cell‑therapy programs has become increasingly challenging, prompting the search for options beyond traditional funding.

Industry observers note that reverse mergers-where a private firm combines with a public shell to gain market access-have surged in popularity. Caribou’s public listing makes it a potential target for such a transaction, offering a ready‑made vehicle for private investors seeking Nasdaq exposure.

If a reverse merger proceeds, it could provide Caribou with the financial resources needed to continue its research while giving a private partner immediate public‑market visibility.